( May 14, 2026, 1:52 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on May 13 affirmed a West Virginia federal judge’s finding that a generic drug maker did not infringe patents describing a compound used in a hypertension drug because a claim term “a pH of 13 or higher” referred to a standard temperature in the field; the panel said it found no clear error in the judge’s claim construction (Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc., No. 24-1641, Fed. Cir., 2026 U.S. App. LEXIS 13688)....